Background/aims: Targeted magnetic resonance imaging/ ultrasound (MRI/US) guided biopsy is an emerging technology that has the potential to change standard of care for the diagnosis and management of prostate cancer. This technology is rapidly proliferating, however quantitative analysis of these trends are unavailable. The objective of this study was to assess urologist opinions regarding implementing MRI/ US imaging into their practices.
Methods: A questionnaire was distributed using research electronic data capture and completed by 291 practicing urologists within the United States registered through the American Urological Association. The survey gathered information regarding demographics, changes in MRI use, opinions on targeted MRI/US guided biopsy, and barriers to implementation. The survey results were analyzed using ANOVA.
Results: Practice setting and geographic region were signifIcantly associated with implementation of MRI/US guided biopsy. Total 72% of urologists in academic centers report using MRI/US targeted biopsy, compared to 38% in solo private practice. In the northeast 68% of urologists report using MRI/US biopsy, compared to 44% in the western United States.
Conclusion: While there are some reservations about employing MRI/US guided biopsy as standard of care in all prostate biopsies, the data suggests urologists support its use, and are making efforts to introduce targeted MRI/US guided biopsy into their practice. Regional and practice setting variations exist in implementation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504798 | PMC |
| http://dx.doi.org/10.1159/000489426 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PI-RADS in Predicting csPCa: A Comparison Between Academic and Nonacademic Centers.
Prostate
December 2024
Urology Unit, Department of Medical, Oral and Biotechnological Sciences, 'G. d'Annunzio University', Chieti, Italy.
Introduction: The introduction of multiparametric prostate magnetic resonance imaging (mpMRI) has revolutionized prostate cancer (PCa) diagnosis, enhancing the localization of clinically significant prostate cancer (csPCa) and guiding targeted biopsies. However, significant disparities in the execution, interpretation, and reporting of prostate MRI examinations across centers necessitate greater standardization and accuracy. This study compares the diagnostic efficacy of mpMRI from academic and nonacademic centers in detecting csPCa and identifies factors associated with csPCa detection.
View Article and Find Full Text PDFImpact of Discordance Between Magnetic Resonance Imaging and Ultrasound Volume Measurements on Prostate Fusion Biopsy Outcomes.
J Urol
December 2024
Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland.
Purpose: To determine whether the difference between MRI-based and ultrasound (US)-based volume measurements are associated with MRI/US-targeted fusion-guided biopsy outcomes.
Materials And Methods: This retrospective, single-center study involved 4177 consecutive patients biopsied between 2010 and 2023 using both MRI/US-targeted fusion and systematic biopsy. Biopsies were indicated because of elevated PSA levels or abnormal multiparametric MRI results.
[Risk Factors for Positive Resection Margins in Robot-Assisted Laparoscopic Radical Prostatectomy after Systematic and MRI-Ultrasound Fusion Guided Prostate Biopsy].
Hinyokika Kiyo
August 2024
The Department of Urology, Japanese Red Cross Wakayama Medical Center.
Article Synopsis
- There was an increased risk of positive resection margins (RMs) in patients who underwent robotic-assisted laparoscopic radical prostatectomy (RARP) after having systematic prostate biopsies.
- The study evaluated 61 patients who had MRI-ultrasonography fusion and systematic biopsies, and found that the RM-positive group generally had a higher clinical stage and a greater proportion of positive biopsy results.
- Logistic regression indicated that the positivity rate of systematic biopsies was a significant risk factor for RM positivity, suggesting that these biopsies might be important for assessing the feasibility of preserving the neurovascular bundles during surgery.
Multimodal approach to optimize biopsy decision-making for PI-RADS 3 lesions on multiparametric MRI.
Clin Imaging
January 2025
Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:
Purpose: To develop and evaluate a multimodal approach including clinical parameters and biparametric MRI-based artificial intelligence (AI) model for determining the necessity of prostate biopsy in patients with PI-RADS 3 lesions.
Methods: This retrospective study included a prospectively recruited patient cohort with PI-RADS 3 lesions who underwent prostate MRI and MRI/US fusion-guided biopsy between April 2019 and February 2024 in a single institution. The study examined demographic data, PSA and PSA density (PSAD) levels, prostate volumes, prospective PI-RADS v2.
Recent Advances in Image-Guided Tissue Sampling.
Cureus
October 2024
Radiology, Royal Free Hospital, London, GBR.
Article Synopsis
- - Recent improvements in image-guided tissue sampling, like CT, US, and MRI-guided biopsies, are enhancing diagnostics in oncology by targeting tissue characteristics effectively.
- - New methods like fusion imaging and technologies such as molecular breast imaging and shear wave elastography are being explored, but ultrasound remains favored for its cost-effectiveness and ease of use.
- - Innovations in biopsy techniques, including augmented reality and robotic assistance, are promising, yet further research and overcoming cost and access issues are necessary for broader implementation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!